Barinthus Biotherapeutics plc. (BRNS)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenue | - | 14,969 | - | |
| Other operating income | 13 | 210 | 577 | |
| Research and development | 7,953 | 11,139 | 11,662 | |
| General and administrative | 15,384 | 13,420 | 7,201 | |
| Total operating expenses | 23,337 | 24,559 | 18,863 | |
| Loss from operations | -23,324 | -9,380 | -18,286 | |
| Other income | 320 | 26 | 20 | |
| Interest income | 523 | 631 | 635 | |
| Interest expense | 12 | 17 | 12 | |
| Research and development incentives | 1,342 | 608 | 693 | |
| Total other income, net | 2,173 | 1,248 | 1,336 | |
| Loss before income tax | -21,151 | -8,132 | -16,950 | |
| Tax benefit | -25 | -3 | -7 | |
| Net loss | -21,126 | -8,129 | -16,943 | |
| Net loss attributable to noncontrolling interest | -2 | -15 | -12 | |
| Net loss attributable to barinthus biotherapeutics plc shareholders | -21,124 | -8,114 | -16,931 | |
| Net loss per share attributable to ordinary shareholders, basic (in usd per share) | -0.52 | -0.21 | -0.43 | |
| Net loss per share attributable to ordinary shareholders, diluted (in usd per share) | -0.52 | -0.21 | -0.43 | |
| Weighted-average ordinary shares outstanding, basic (in shares) | 40,343,521 | 39,419,447 | 39,041,111 | |
| Weighted-average ordinary shares outstanding, diluted (in shares) | 40,343,521 | 39,419,447 | 39,041,111 | |